Drug Profile
JAB 3068
Alternative Names: JAB-3068Latest Information Update: 02 Aug 2021
Price :
$50
*
At a glance
- Originator Jacobio Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine phosphatase non receptor type 11 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-small cell lung cancer; Squamous cell cancer
- Phase I Solid tumours
Most Recent Events
- 02 Aug 2021 Phase I development for Solid tumours is ongoing in USA (Jacobio Pharmaceuticals pipeline, August 2021)
- 02 Aug 2021 Phase-II clinical trials in Non-small cell lung cancer (Monotherapy) in China (PO) (Jacobio Pharmaceuticals pipeline, August 2021)
- 02 Aug 2021 Phase-II clinical trials in Squamous cell cancer (Monotherapy) in China (PO) (Jacobio Pharmaceuticals pipeline, August 2021)